TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32798
Drug: Diazepam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam with benzyl alcohol (0.35 mg/kg diazepam, 1.1 mg/kg benzyl alcohol)
Study: 19825327
Drug: MEL‐OD (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL‐OD (test formulation)
Study: 19825327
Drug: Mobic (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobic (reference formulation)
Study: 9286853
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg and 100 mg
Study: 7934778
Drug: Low-dose inhalation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhalation
Study: 7934778
Drug: High-dose inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhalation
Study: 25633584
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment before menstruation onset (Group A)
Study: 25633584
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment at the onset of menstruation (Group B)
Study: 24000658
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with trimeperidine in combination with nefopam constant infusion
Study: 24000658
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with trimeperidine in combination with nefopam bolus
Study: 18022165
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice per day for 12 weeks)
Study: 12684147
Drug: ML Cu
Normalized name: SYRINGE 10-12ML CURVED TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML Cu 375 sl
Study: 9211677
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg of ganciclovir per hour implant
Study: 9211677
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg of ganciclovir per hour implant
Study: 1412113
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 10 mg/kg every four hours for 48 hours (group A)
Study: 1412113
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 2 mg/kg every four hours for 48 hours (group B)
Study: 1412113
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous corticosteroids (group C)
Study: 31416155
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 20,000 IU/week (in subgroup with baseline 25(OH)D <50 nmol/L)
Study: 27390052
Drug: MK0431A 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0431A 50 mg/500 mg tablet
Study: 27390052
Drug: MK0431A 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0431A 50 mg/850 mg tablet
Study: 24758075
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + LEF therapy
Study: 22643324
Drug: AAQ +
Normalized name: Abiraterone Acetate
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AAQ + AMX (artesunate-amodiaquine plus amoxicillin)
Study: 18953863
Drug: Oral lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lamivudine (100 mg/d)
Study: 10760037
Drug: IFN-alpha with
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha with ribavirin (1-1.2 g per day)
Study: 7721636
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose irradiation (75.6 CGE) using conformal protons
Study: 7721636
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose irradiation (67.2 Gy) using photons
Study: 1976343
Drug: terfenadine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 180 mg three times daily
Study: 31742459
Drug: Pro-vaccine posts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-vaccine posts
Study: 31742459
Drug: Anti-vaccine posts
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vaccine posts
Study: 28029173
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 200 mg/d)
Study: 21733570
Drug: Prednisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.5 mg/kg daily for 8 months)
Study: 21733570
Drug: Tamoxifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (0.5 mg/kg daily for 8 months)
Study: 19863338
Drug: ABVD consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD consolidation therapy
Study: 19863338
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) consolidation
Study: 8137469
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of TACE followed by PEI
Study: 6137969
Drug: Midazolam 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.07 mg/kg
Study: 2913250
Drug: Midazolam 0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.13 mg/kg
Study: 349395
Drug: X-ray therapy
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-ray therapy (XRT)
Study: 29117336
Drug: Paclitaxel/carboplatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/carboplatin treatment
Study: 29117336
Drug: Older age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older age, bevacizumab treatment, bowel resection
Study: 24432669
Drug: Sulfasalazine enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine enteric‐coated tablet (SECT)
Study: 22900440
Drug: Xylitol treatment
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol treatment (chewing gum for mothers and tablets for children, consumed three times/day for three months)
Study: 22900440
Drug: Xylitol treatment
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol treatment (experimental group)
Study: 20183464
Drug: Complete case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete case (CC) analysis of covariance (ANCOVA)
Study: 17166358
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (infusion of insulin if blood glucose >6.1 mmol/L, maintenance at 4.4‐6.1 mmol/L)
Study: 17166358
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (infusion of insulin if blood glucose >11.9 mmol/L, maintenance at 10.0‐11.1 mmol/L)
Study: 8707580
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (Fenistil gel)
Study: 9413892
Drug: Xylocain ointment
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocain ointment 5%
Study: 8214944
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) pretreatment (30 mg/kg)
Study: 8924134
Drug: Non-steroid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid treatment (Control)
Study: 21666396
Drug: Glow gel
Normalized name: Coppertone Glow Gel SPF 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glow gel hand washing without hand hygiene education
Study: 21666396
Drug: Glow gel
Normalized name: Coppertone Glow Gel SPF 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glow gel hand washing with hand hygiene education
Study: 18443512
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for chronic postoperative groin pain
Study: 17163237
Drug: Alendronic acid
Normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronic acid 70 mg weekly
Study: 17163237
Drug: Risedronic acid
Normalized name: Risedronic acid
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronic acid 35 mg weekly
Study: 2069096
Drug: Tebufelone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebufelone 50 mg
Study: 2069096
Drug: Tebufelone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebufelone 100 mg
Study: 2069096
Drug: Tebufelone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebufelone 200 mg
Study: 2069096
Drug: Tebufelone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebufelone 25 mg
Study: 2069096
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg ASA
Study: 7049154
Drug: Multiload Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiload Copper 250 (ML Cu 250)
Study: 31322739
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg intravenously every 3 weeks over 18 months
Study: 31322739
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg
Study: 30496705
Drug: Montmorency cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency cherry (MC) supplementation (235 mg/day anthocyanins)
Study: 29391271
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA-FFA) 500 mg, twice daily for 6 months
Study: 20026571
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and education schemes held twice weekly for eight weeks
Study: 11300442
Drug: Abciximab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (bolus 0.25 mg/kg body weight, infusion 10 microg per min for 12 h)
Study: 11300442
Drug: Tirofiban (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (bolus 10 microg/kg, infusion 0.15 microg/kg per min for 72 h)
Study: 11300442
Drug: Eptifibatide (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (bolus 180 microg/kg, infusion 2 microg/kg per min for 72 h)
Study: 3522528
Drug: Timentin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timentin (3 g/200 mg injections)
Study: 3522528
Drug: Cefamandole (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (0.75 g injections)
Study: 31609301
Drug: L-Tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Tyrosine (150 mg·kg)
Study: 29498933
Drug: myo-inositol +
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: myo-inositol + folic acid (4000 mg myo-inositol + 400 μg folic acid per day)
Study: 25659187
Drug: Ziprasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone monotherapy for 12 weeks
Study: 20692693
Drug: PRB28 (peginterferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRB28 (peginterferon alfa‐2b, ribavirin, and boceprevir 800 mg three times a day for 28 weeks)
Study: 20692693
Drug: low-dose PRB48
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose PRB48 (low-dose ribavirin plus peginterferon alfa‐2b and boceprevir for 48 weeks)
Study: 26854486
Drug: Isotretinoin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.25 mg/kg/day)
Study: 20524999
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (0.066 mg/kg, max 4 mg)
Study: 16624969
Drug: Sunscreen use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen use daily
Study: 12654707
Drug: Candesartan (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (800 microg/min) + L-NMMA (7 micromol/min)
Study: 10919416
Drug: Amrinone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.5 mg x kg(‐1) bolus over 15 min, followed by 10 microg x kg(‐1) x min(‐1) infusion)
Study: 10919416
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume bolus followed by placebo infusion)
Study: 8979280
Drug: Dapiprazole 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapiprazole 0.5% eye drops administered 3 times daily as adjunctive therapy to timolol 0.5% eye drops twice daily
Study: 6723452
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (comparison treatments)
Study: 30387335
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) after surgical excision and radiotherapy
Study: 27339806
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folic acid, 25 mg Vitamin B6, and Vitamin B12
Study: 20625068
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta‐1a (30 micrograms once weekly for 2 years)
Study: 20625068
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once weekly for 2 years)
Study: 18565107
Drug: Levetiracetam (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (3000 mg/day)
Study: 11791150
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sucrose (2160 kJ, 575 ml)
Study: 11791150
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of maltose (2160 kJ, 575 ml)
Study: 11791150
Drug: Water control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water control (67 kJ, 575 ml)
Study: 11791150
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of sucrose
Study: 11791150
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of maltose
Study: 2178534
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of warfarin, beginning 3 days before catheter insertion and continuing for 90 days
Study: 8423275
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate
Study: 31272930
Drug: Semaglutide once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide once weekly
Study: 21258206
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with percutaneous microwave ablation (PMWA) and adoptive immunotherapy
Study: 17331963
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 800 microg/day
Study: 16371870
Drug: MMR Berna
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR Berna vaccine
Study: 16371870
Drug: Licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccine M-M-R-Vax (Merck & Co.)
Study: 12526191
Drug: Bovine-derived bone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine-derived bone protein extract with 12.5 micrograms/mg DFDBA
Study: 12526191
Drug: Bovine-derived bone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine-derived bone protein extract with 25.0 micrograms/mg DFDBA
Study: 9594863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NO treatment)
Study: 7879322
Drug: Intraurethral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral administration of prostaglandin E1
Study: 7879322
Drug: Intracavernous administration
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous administration of half the dose of prostaglandin E1
Study: 227069
Drug: econazole-triamcinolon combination
Normalized name: econazole / triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: econazole-triamcinolon combination
Study: 19014837
Drug: LC15-0444 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC15-0444 200 mg
Study: 20002082
Drug: LC15-0444 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC15-0444 400 mg
Study: 19014837
Drug: LC15-0444 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC15-0444 600 mg
Study: 10807761
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with 2 mg estradiol + 1 mg norethisterone
Study: 8923067
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with dipyrone (initially 2.0 g i.v. and 1.0 g/2 ml i.v. at 4, 8 and 16 h)
Study: 1366330
Drug: Alginete pills
Normalized name: sodium alginate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginete pills with diet
Study: 28957833
Drug: Clear Care
Normalized name: Clear care plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear Care (CC)
Study: 25335348
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% clobetasol proprionate lotion
Study: 20576091
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30‐70 mg/d
Study: 16061764
Drug: Pharmacotherapy (paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride)
Study: 2667400
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg)
Study: 11949768
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) + Triazolam
Study: 11949768
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) + Temazepam
Study: 10780808
Drug: Ethanol (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0 g/kg)
Study: 10349927
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (0.7 ml x kg(‐1)) via lumbar epidural block
Study: 7572122
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine injection (1 mg/kg)
Study: 795441
Drug: Colestipol HCl
Normalized name: colestipol HCl
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol HCl 10 g twice daily
Study: 28461256
Drug: Veliparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (120 mg) with carboplatin/paclitaxel
Study: 20650587
Drug: 25-s injection
Normalized name: (S)-2,5-Diaminopentanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-s injection duration
Study: 20650587
Drug: 35-s injection
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35-s injection duration
Study: 22298019
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (0.6 mg/h) for 2 h a day for 6 days
Study: 22298019
Drug: Oral PETN
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PETN (80 mg) once a day for 6 days
Study: 15900289
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg AZD3582
Study: 15900289
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg AZD3582
Study: 12357161
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg rofecoxib
Study: 12576917
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: three 8‐mg doses of ondansetron intravenously at 4‐hour intervals plus dexamethasone 20 mg intravenously from the start of chemotherapy, followed by dexamethasone 5 mg intravenously every 12 hours.
Study: 12576917
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: three 8‐mg doses of ondansetron intravenously at 24‐hour intervals plus dexamethasone as in Arm A.
Study: 12576917
Drug: Female patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female patients during chemotherapy cycles.
Study: 9609084
Drug: Abciximab treatment
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab treatment
Study: 9609084
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with standard-dose heparin
Study: 2760974
Drug: Rice powder
Normalized name: White rice powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice powder electrolyte solution
Study: 12715722
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant IL-1 receptor antagonist) with or without methotrexate
Study: 29795141
Drug: PSA 2.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 2.5-4 ng/mL
Study: 29795141
Drug: PSA 4.1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 4.1-6 ng/mL
Study: 29795141
Drug: PSA 6-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 6-10 ng/mL
Study: 23713767
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg in fed state
Study: 23713767
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg in fasted state
Study: 22573670
Drug: English words
Approvals — FDA: no, EMA: no, PMDA: no
Description: English words with negative valence (e.g., 'violence')
Study: 22573670
Drug: English words
Approvals — FDA: no, EMA: no, PMDA: no
Description: English words with positive and neutral valence (e.g., 'holiday', 'theory')
Study: 20536509
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (40 g/day)
Study: 20536509
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement (0 g/day)
Study: 17969366
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg/Indapamide 0.625 mg